The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 study of HLX07 plus serplulimab with or without chemotherapy versus serplulimab plus chemotherapy as first-line therapy in advanced squamous non-small cell lung cancer.
 
Yi-Long Wu
Honoraria - AstraZeneca; BeiGene Beijing; Boehringer Ingelheim; Bristol-Myers Squibb/China; Hengrui Pharmaceutical; MSD Oncology; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Roche; Takeda
Research Funding - BMS (Inst); Boehringer Ingelheim (Inst); Pfizer (Inst); Roche (Inst)
 
Zhen Wang
No Relationships to Disclose
 
Xiaorong Dong
No Relationships to Disclose
 
Jingzhang Li
No Relationships to Disclose
 
Lin Wu
No Relationships to Disclose
 
Liang Han
No Relationships to Disclose
 
XingYa Li
No Relationships to Disclose
 
Aimin Zang
No Relationships to Disclose
 
Wen Li
No Relationships to Disclose
 
Guilan Wen
No Relationships to Disclose
 
Wen Lin
No Relationships to Disclose
 
Xuhui Hu
Employment - Shanghai Henlius Biotech
 
Futang Yang
Employment - Shanghai Henlius Biotech
 
Haoyu Yu
Employment - Shanghai Henlius Biotech
 
Qingyu Wang
Employment - Shanghai Henlius Biotech
 
Jing Li
Employment - Shanghai Henlius Biotech